Navigation Links
CLAAD Warns of Increase in Prescription Drug Overdoses
Date:11/12/2012

WASHINGTON, Nov. 12, 2012 /PRNewswire-USNewswire/ -- Today, a national organization dedicated to reducing prescription drug abuse urged communities to take extra precautions to prevent medication overdoses.  The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) warned that pain pills without added safety features are expected to flood back into communities in the coming weeks unless the Food and Drug Administration (FDA) takes preventive action. 

In recent years, the makers of the powerful opioid pain relievers OxyContin and Opana removed their traditional products from the market in favor of new versions designed to impede certain forms of intentional abuse.  Preliminary, peer-reviewed evidence indicates that dealers and abusers have less interest in the new drugs with abuse-deterrent features.[1]  The new medications cost no more to consumers than their prior formulations. 

"Pharmaceutical companies have an obligation to make their products safer," said Michael Barnes, spokesman for CLAAD. 

Several drug companies have asked the FDA to approve generic versions of these medications that do not have abuse-deterrent properties.  The FDA could allow the old formulations of the drugs to return to market as early as January 2013. 

"Parents, health care providers, and law enforcement must be prepared to confront the resurgence of more readily abused pain medications, and the overdoses that could follow," Barnes said. 

Earlier this month, CLAAD and nine other public health and safety organizations sent a letter to the FDA urging it to take swift action to foster the widespread adoption of abuse-deterrent medications and to prevent the marketing of generic versions of the drugs that do not have similar safety features. 

A bill before the U.S. House of Representatives, H.R. 6160, would require all manufacturers of opioid pain relievers to utilize abuse-deterrent technologies.  However, the measure is not likely to pass before January.

About the Center for Lawful Access and Abuse Deterrence
The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) enables health professionals, law enforcement, businesses, and government, among other entities, to share resources and work together to reduce prescription drug abuse, addiction, and overdoses. CLAAD's National Prescription Drug Abuse Prevention Strategy has been endorsed by 30 non-profit organizations and may be accessed online at www.claad.org.  Follow @claad_coalition on Twitter.

[1] Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. New England Journal of Medicine. 2012;367(2):187-189.


'/>"/>
SOURCE CLAAD
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Gateway Foundation Warns K2 is Bad News: K2 Poses Serious Health Risks
2. Solos Endoscopy Sales Increase by More than 35% for the Month of October
3. Frost & Sullivan: Global Increase in Adoption of Real-Time Location Systems Depends on Technological Innovations
4. Mesa Labs Increases Quarterly Dividend
5. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
6. Medbox Announces Increase in Shareholder Base and Record Revenue Generated in Q3
7. Watson Third Quarter 2012 Non-GAAP Diluted EPS Increases 24% to $1.35; Net Revenue Increases 19% to $1.29 Billion
8. Global eClinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies: MarketResearchReports.Biz
9. Glenmarks Consolidated Revenue Increases by 18.9% to Rs. 12551.9 Mn for Q2 FY12-13
10. Mylan Reports a 51% Increase in Third Quarter 2012 Adjusted Diluted EPS to $0.83
11. Call for Submissions: ICAP Patent Brokerage Announces Expansion of Life Sciences Practice and Increased Buyer Interest in Related Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... PUNE, India , May 25, 2016 /PRNewswire/ ... Pipeline Review, H1 2016"market research report that provides ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ...
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und ... Überlegenheit in ‚ausgezeichneter plus guter ... Colons    ,      (Logo: ... gab heute neue positive Daten von der MORA-Studie ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, ... who lost their lives in military battle for the country. The nonprofit Hope ... to provide more programs that empower independence for disabled military veterans, as well as ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent Pharma ... drugs, biologics, consumer health and global clinical supply services, today announced two key ... the company’s continued investment and strategic growth plans in the Asia Pacific region. ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... chain solutions, today announced the organization has earned its ISO 13485 certification, indicating ... is compliant with all rules and policies associated with ISO quality standard 13485. ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic surgeon ... officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an International ... May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused on ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... oncology professionals, has added National Cancer Institute-designated University of Virginia (UVA) Cancer ... this new partnership, OncLive’s editorial and marketing teams will publicize and promote public ...
Breaking Medicine News(10 mins):